Tuesday, October 19, 2010 4:48:08 PM
"There has been a large increase in interest in our PNT product line and glaucoma treatment, ever since NAM starting its marketing rollout in neighboring India last month," states G. Richard Smith, CEO of Sunridge. Mr. Smith goes on to say, "that NAM's marketing plan is both impressive and aggressive, and that their sales have already surpassed original estimates."
"Bangladesh is the sixth largest country in the world by population, and should be a major market for our two-minute non-invasive glaucoma treatment, and a significant revenue stream for our company," states Mr. Smith.
Leo D. Bores, M.D., a medical consultant for Sunridge, will be traveling throughout India for the next two weeks working with NAM's personnel, training doctors, treating patients and providing informational seminars to the public. NAM's personnel have stated, that Dr. Bores's schedule will likely be changed to include stops in Bangladesh.
Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International (www.oi-pnt.com).
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM